

Anita H Clayton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9274894/publications.pdf>

Version: 2024-02-01

139
papers

7,020
citations

57758

44
h-index

62596

80
g-index

165
all docs

165
docs citations

165
times ranked

4291
citing authors

#	ARTICLE	IF	CITATIONS
1	The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. <i>CNS Spectrums</i> , 2022, 27, 281-289.	1.2	9
2	An Innovative Model of Behavior Management to Address Behavioral Emergencies in the Acute Medical Inpatient Setting: Pilot Data. <i>Journal of Clinical Psychology in Medical Settings</i> , 2022, 29, 54-61.	1.4	0
3	Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin. <i>Sexual Medicine</i> , 2022, 10, 100476-100476.	1.6	8
4	Pharmacotherapy for Sexual Dysfunction in Women. <i>Current Psychiatry Reports</i> , 2022, , 1.	4.5	0
5	Safety Profile of Bremelanotide Across the Clinical Development Program. <i>Journal of Women's Health</i> , 2022, 31, 171-182.	3.3	0
6	Including partners in discussions of sexual side effects from breast cancer: a qualitative study of survivors, partners, and providers. <i>Supportive Care in Cancer</i> , 2022, 30, 4935-4944.	2.2	5
7	Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 913-930.	2.4	8
8	Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. <i>Journal of Women's Health</i> , 2022, 31, 391-400.	3.3	4
9	The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. <i>Sexual Medicine Reviews</i> , 2021, 9, 36-56.	2.9	43
10	Addressing sexual concerns of female breast cancer survivors and partners: a qualitative study of survivors, partners, and oncology providers about Internet intervention preferences. <i>Supportive Care in Cancer</i> , 2021, 29, 7451-7460.	2.2	9
11	Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 39-45.	0.8	3
12	Response to Balon's Commentary: Is Basson's Model of Sexual Response Relevant?. <i>Journal of Sex and Marital Therapy</i> , 2021, , 1-3.	1.5	3
13	Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. <i>CNS Spectrums</i> , 2020, 25, 50-63.	1.2	22
14	Evaluation of safety for flibanserin. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1-8.	2.4	15
15	Effects of Alcohol Administered with Flibanserin in Healthy Premenopausal Women: A Randomized, Double-Blind, Single-Dose Crossover Study. <i>Journal of Sexual Medicine</i> , 2020, 17, 83-93.	0.6	7
16	Effect of Brexpiprazole on Prolactin and Sexual Functioning. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 560-567.	1.4	8
17	Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder. <i>Journal of Women's Health</i> , 2020, 29, 806-814.	3.3	3
18	Lumping, Splitting, and Treating: Therapies Are Needed for Women With Overlapping Sexual Dysfunctions. <i>Sexual Medicine Reviews</i> , 2019, 7, 551-558.	2.9	2

#	ARTICLE	IF	CITATIONS
19	Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. <i>Journal of Sexual Medicine</i> , 2019, 16, 1226-1235.	0.6	12
20	Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. <i>Journal of Sexual Medicine</i> , 2019, 16, 1638-1649.	0.6	29
21	Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects. <i>Sexual Medicine</i> , 2019, 7, 418-424.	1.6	6
22	Female Sexual Dysfunction. <i>Medical Clinics of North America</i> , 2019, 103, 681-698.	2.5	76
23	Evaluation of Flibanserin Safety: Comparison with Other Serotonergic Medications. <i>Sexual Medicine Reviews</i> , 2019, 7, 380-392.	2.9	5
24	Effects of Timing of Flibanserin Administration Relative to Alcohol Intake in Healthy Premenopausal Women: A Randomized, Double-Blind, Crossover Study. <i>Journal of Sexual Medicine</i> , 2019, 16, 1779-1786.	0.6	6
25	Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. <i>Obstetrics and Gynecology</i> , 2019, 134, 899-908.	2.4	242
26	Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. <i>Journal of Sexual Medicine</i> , 2019, 16, 1885-1894.	0.6	8
27	Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. <i>Obstetrics and Gynecology</i> , 2019, 134, 909-917.	2.4	186
28	Evaluation and Management of Hypoactive Sexual Desire Disorder. <i>Sexual Medicine</i> , 2018, 6, 59-74.	1.6	42
29	Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. <i>Sexual Medicine Reviews</i> , 2018, 6, 367-383.	2.9	16
30	Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study. <i>Journal of Sexual Medicine</i> , 2018, 15, 43-51.	0.6	11
31	Sex Differences in the Treatment of Sexual Dysfunction. <i>Current Psychiatry Reports</i> , 2018, 20, 18.	4.5	9
32	Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. <i>Sexual Medicine Reviews</i> , 2018, 6, 358-366.	2.9	9
33	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. <i>Mayo Clinic Proceedings</i> , 2018, 93, 467-487.	3.0	166
34	Efficacy of Bremelanotide for HSDD in Women: RECONNECT Open-Label Extension Phase Results [8Q]. <i>Obstetrics and Gynecology</i> , 2018, 131, 186S-186S.	2.4	4
35	Expert opinion on existing and developing drugs to treat female sexual dysfunction. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 223-230.	2.4	14
36	A Brief Version of the Sexual Interest and Desire Inventory—Female With 4 Core Items. <i>Journal of Sexual Medicine</i> , 2018, 15, 1370-1371.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features). <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	10
38	Is Flibanserin Meaningfully Superior to Placebo?. <i>Journal of Sex and Marital Therapy</i> , 2017, 43, 218-222.	1.5	4
39	Quantitative and Qualitative Research in HSDD: The Difference Between Testing Theory and Generating New Theories. <i>Journal of Sex and Marital Therapy</i> , 2017, 43, 223-227.	1.5	3
40	Women's Mental Health: Progress and Realities. <i>Psychiatric Clinics of North America</i> , 2017, 40, xiii-xiv.	1.3	0
41	Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. <i>Clinical Therapeutics</i> , 2017, 39, 514-526.e14.	2.5	14
42	Female Sexual Dysfunction. <i>Psychiatric Clinics of North America</i> , 2017, 40, 267-284.	1.3	53
43	Hypoactive Sexual Desire Disorder. <i>Mayo Clinic Proceedings</i> , 2017, 92, 114-128.	3.0	158
44	What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder. <i>Sexual Medicine</i> , 2017, 5, e73-e83.	1.6	8
45	Flibanserin: From Bench to Bedside. <i>Sexual Medicine Reviews</i> , 2017, 5, 461-469.	2.9	26
46	Effects of vilazodone on sexual functioning in healthy adults. <i>International Clinical Psychopharmacology</i> , 2017, 32, 27-35.	1.7	17
47	Standards in Studies of Psychotherapy and Pharmacotherapy Interventions for HSDD. <i>Journal of Sex and Marital Therapy</i> , 2017, 43, 206-209.	1.5	2
48	Clinical role of brexpiprazole in depression and schizophrenia. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 299-306.	2.0	18
49	Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 21-24.	0.1	1
50	Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 1467.	2.2	15
51	Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. <i>CNS Spectrums</i> , 2016, 21, 367-378.	1.2	45
52	Hypoactive Sexual Desire Disorder: Separating Fact from Fiction. <i>CNS Spectrums</i> , 2016, 21, 9-11.	1.2	3
53	Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. <i>Women's Health</i> , 2016, 12, 325-337.	1.5	75
54	Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions—Part II. <i>Journal of Sexual Medicine</i> , 2016, 13, 1888-1906.	0.6	116

#	ARTICLE	IF	CITATIONS
55	Sexual Dysfunction Due to Psychotropic Medications. <i>Psychiatric Clinics of North America</i> , 2016, 39, 427-463.	1.3	56
56	Sexual Function Across Aging. <i>Current Psychiatry Reports</i> , 2016, 18, 28.	4.5	15
57	Models vs. Realities in Female Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2015, 12, 1977-1978.	0.6	2
58	Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2015, 30, 307-315.	1.7	7
59	Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo. <i>International Clinical Psychopharmacology</i> , 2015, 30, 216-223.	1.7	28
60	Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective. <i>Journal of Sexual Medicine</i> , 2015, 12, 2451-2458.	0.6	57
61	Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2015, 12, 2036-2048.	0.6	78
62	A Pooled Analysis of the Efficacy of Desvenlafaxine for the Treatment of Major Depressive Disorder in Perimenopausal and Postmenopausal Women. <i>Journal of Women's Health</i> , 2015, 24, 281-290.	3.3	20
63	The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. <i>CNS Drugs</i> , 2015, 29, 915-933.	5.9	103
64	Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 562-569.	2.2	32
65	Antidepressants and Sexual Dysfunction: Mechanisms and Clinical Implications. <i>Postgraduate Medicine</i> , 2014, 126, 91-99.	2.0	117
66	Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. <i>Menopause</i> , 2014, 21, 799-806.	2.0	17
67	Female Sexual Interest/Arousal Disorder: A Diagnosis Out of Thin Air. <i>Archives of Sexual Behavior</i> , 2014, 43, 1227-1229.	1.9	48
68	Sexual dysfunction associated with major depressive disorder and antidepressant treatment. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1361-1374.	2.4	100
69	Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. <i>BMC Research Notes</i> , 2014, 7, 459.	1.4	18
70	Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. <i>CNS Spectrums</i> , 2014, 19, 182-196.	1.2	4
71	Prevalence of Substance Misuse in New Patients in an Outpatient Psychiatry Clinic Using a Prescription Monitoring Program. <i>primary care companion for CNS disorders</i> , The, 2014, 16, .	0.6	7
72	Etiology of Female Sexual Dysfunction. <i>Women's Health</i> , 2013, 9, 135-137.	1.5	18

#	ARTICLE	IF	CITATIONS
73	The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder. <i>Journal of Sexual Medicine</i> , 2013, 10, 2465-2476.	0.6	47
74	Validity of the Decreased Sexual Desire Screener for Diagnosing Hypoactive Sexual Desire Disorder. <i>Journal of Sex and Marital Therapy</i> , 2013, 39, 132-143.	1.5	24
75	An Evaluation of Sexual Functioning in Employed Outpatients with Major Depressive Disorder Treated with Desvenlafaxine 50mg or Placebo. <i>Journal of Sexual Medicine</i> , 2013, 10, 768-776.	0.6	23
76	The Impact of Antidepressant-Associated Sexual Dysfunction on Treatment Adherence in Patients with Major Depressive Disorder. <i>Current Psychiatry Reviews</i> , 2013, 9, 293-301.	0.9	3
77	Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1010-1017.	2.2	49
78	Insomnia and attention deficit hyperactivity disorder in pediatrics: a checklist for parents. <i>Innovations in Clinical Neuroscience</i> , 2013, 10, 19-22.	0.1	0
79	Depression in Premenopausal Women With HSDD. <i>Psychosomatic Medicine</i> , 2012, 74, 305-311.	2.0	26
80	Intended or Unintended Consequences? The Likely Implications of Raising the Bar for Sexual Dysfunction Diagnosis in the Proposed DSM-V Revisions: 1. For Women with Incomplete Loss of Desire or Sexual Receptivity. <i>Journal of Sexual Medicine</i> , 2012, 9, 2027-2039.	0.6	38
81	Intended or Unintended Consequences? The Likely Implications of Raising the Bar for Sexual Dysfunction Diagnosis in the Proposed DSM-V Revisions: 2. For Women with Loss of Subjective Sexual Arousal. <i>Journal of Sexual Medicine</i> , 2012, 9, 2040-2046.	0.6	27
82	The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men. <i>Journal of Sexual Medicine</i> , 2012, 9, 821-829.	0.6	14
83	Understanding Antidepressant Mechanism of Action and Its Effect on Efficacy and Safety. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e11.	2.2	3
84	Menopausal Status in Breast Cancer Patients with Past Chemotherapy Determines Long-Term Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2011, 8, 1486-1494.	0.6	35
85	Should Sexual Desire and Arousal Disorders in Women Be Merged?. <i>Archives of Sexual Behavior</i> , 2011, 40, 217-219.	1.9	46
86	eDiary and Female Sexual Distress Scale in Evaluating Distress in Hypoactive Sexual Desire Disorder (HSDD). <i>Journal of Sex Research</i> , 2011, 48, 565-572.	2.5	22
87	GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 34-6.	0.1	50
88	Analysis by Age and Sex of Efficacy Data From Placebo-Controlled Trials of Desvenlafaxine in Outpatients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 294-299.	1.4	21
89	Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. <i>Menopause</i> , 2010, 17, 700-711.	2.0	46
90	Standards for Clinical Trials in Sexual Dysfunction in Women: Research Designs and Outcomes Assessment. <i>Journal of Sexual Medicine</i> , 2010, 7, 541-560.	0.6	37

#	ARTICLE	IF	CITATIONS
91	Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2010, 7, 3918-3928.	0.6	37
92	Cutoff Score of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder. <i>Journal of Women's Health</i> , 2010, 19, 2191-2195.	3.3	23
93	The pathophysiology of hypoactive sexual desire disorder in women. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 110, 7-11.	2.3	66
94	Female Sexual Dysfunction. <i>Psychiatric Clinics of North America</i> , 2010, 33, 323-338.	1.3	35
95	The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia. <i>Psychiatry</i> , 2010, 7, 20-3.	0.3	3
96	Sexual Functioning of Latino Women Seeking Outpatient Gynecologic Care. <i>Journal of Sexual Medicine</i> , 2009, 6, 61-69.	0.6	9
97	Validation of the Decreased Sexual Desire Screener (DSDS): A Brief Diagnostic Instrument for Generalized Acquired Female Hypoactive Sexual Desire Disorder (HSDD). <i>Journal of Sexual Medicine</i> , 2009, 6, 730-738.	0.6	135
98	Continuing Medical Education: The Impact of Mental Illness and Psychotropic Medications on Sexual Functioning: The Evidence and Management (CME). <i>Journal of Sexual Medicine</i> , 2009, 6, 1200-1211.	0.6	47
99	Female Sexual Dysfunction. <i>Obstetrics and Gynecology Clinics of North America</i> , 2009, 36, 861-876.	1.9	22
100	An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder. <i>CNS Spectrums</i> , 2009, 14, 183-195.	1.2	55
101	Distressing Sexual Problems in United States Women Revisited. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1698-1706.	2.2	85
102	The blood brain barrier and the role of cytokines in neuropsychiatry. <i>Psychiatry</i> , 2009, 6, 18-22.	0.3	68
103	Validation of the Female Sexual Distress Scale-Revised for Assessing Distress in Women with Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2008, 5, 357-364.	0.6	470
104	Physician Attitudes Regarding Hypoactive Sexual Desire Disorder in a Primary Care Clinic: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2008, 5, 640-645.	0.6	34
105	Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls. <i>Schizophrenia Research</i> , 2008, 105, 287-288.	2.0	10
106	The Impact of Physical Illness on Sexual Dysfunction. , 2008, 29, 70-88.		62
107	Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment. <i>Journal of Psychiatric Practice</i> , 2008, 14, 13-21.	0.7	54
108	Recognition of depression among women presenting with menopausal symptoms. <i>Menopause</i> , 2008, 15, 758-767.	2.0	13

#	ARTICLE	IF	CITATIONS
109	Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender×age interactions. <i>International Clinical Psychopharmacology</i> , 2007, 22, 226-229.	1.7	23
110	Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 457-466.	1.8	180
111	Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder. <i>Journal of Sexual Medicine</i> , 2007, 4, 917-929.	0.6	115
112	ORIGINAL ARTICLES: Epidemiology and Neurobiology of Female Sexual Dysfunction. <i>Journal of Sexual Medicine</i> , 2007, 4, 260-268.	0.6	84
113	Assessing the Onset of Antidepressant-Induced Sexual Dysfunction Using Interactive Voice Response Technology. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 525-532.	2.2	20
114	Symptoms of Sexual Dysfunction in Patients Treated for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1860-1866.	2.2	24
115	Reliability and Validity of the Sexual Interest and Desire Inventory—Female (SIDI-F), a Scale Designed to Measure Severity of Female Hypoactive Sexual Desire Disorder. <i>Journal of Sex and Marital Therapy</i> , 2006, 32, 115-135.	1.5	133
116	Reliability and Construct Validity of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14). <i>Journal of Sex and Marital Therapy</i> , 2006, 32, 43-52.	1.5	176
117	A Double-blind Comparison Between Bupropion XL and Venlafaxine XR. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 482-488.	1.4	80
118	Burden of phase-specific sexual dysfunction with SSRIs†. <i>Journal of Affective Disorders</i> , 2006, 91, 27-32.	4.1	99
119	Serotonin 2A ~1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects. <i>Neuropsychopharmacology</i> , 2006, 31, 2281-2288.	5.4	90
120	Bupropion Extended Release Compared With Escitalopram. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 736-746.	2.2	114
121	Female Sexual Dysfunctions: What Controversy?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 991-992.	2.2	16
122	Major depressive disorder, antidepressants, and sexual dysfunction. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 6, 33-7.	2.2	29
123	ORIGINAL RESEARCH—WOMEN'S SEXUAL DYSFUNCTIONS: The Sexual Interest and Desire Inventory—Female (SIDI—F): Item Response Analyses of Data from Women Diagnosed with Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2005, 2, 801-818.	0.6	50
124	Potential Role of Androgens in the Treatment of Hypoactive Sexual Desire in Women. <i>Women's Health</i> , 2005, 1, 191-193.	1.5	1
125	15 Years of Clinical Experience With Bupropion HCl. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2005, 7, 106-13.	0.6	225
126	Clinical Evaluation and Management Strategy for Sexual Dysfunction in Men and Women. <i>Journal of Sexual Medicine</i> , 2004, 1, 49-57.	0.6	155

#	ARTICLE	IF	CITATIONS
127	Bupropion Sustained Release for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 339-342.	1.4	163
128	A Placebo-Controlled Trial of Bupropion SR as an Antidote for Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 62-67.	2.2	178
129	Sexual function and dysfunction in women. <i>Psychiatric Clinics of North America</i> , 2003, 26, 673-682.	1.3	49
130	Chronic episodic disorders in women. <i>Psychiatric Clinics of North America</i> , 2003, 26, 725-740.	1.3	35
131	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2003, 18, 151-156.	1.7	10
132	Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2003, 18, 151-156.	1.7	65
133	Combination Therapy in the Treatment of Major Depressive Disorder Complicated by Fibromyalgia and Menopause. <i>Psychosomatics</i> , 2002, 43, 491-493.	2.5	4
134	Prevalence of Sexual Dysfunction Among Newer Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 357-366.	2.2	450
135	Female sexual dysfunction related to depression and antidepressant medications. <i>Current Women's Health Reports</i> , 2002, 2, 182-7.	0.2	42
136	The Design and Evaluation of a Group Research Experience During Psychiatric Residency Training. <i>Academic Psychiatry</i> , 2001, 25, 68-76.	0.9	4
137	Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 185-190.	2.2	70
138	Assessment of sexual functioning during the menstrual cycle. <i>Journal of Sex and Marital Therapy</i> , 1999, 25, 281-291.	1.5	33
139	Positron-Emission Tomography and Personality Disorders. <i>Neuropsychopharmacology</i> , 1994, 10, 21-28.	5.4	244